Skip to content

HS2 US Liver Reader Study

HS2 US Liver Reader Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05783284
Enrollment
22
Registered
2023-03-24
Start date
2023-03-02
Completion date
2023-03-04
Last updated
2023-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reader Study

Keywords

Holographic visualization

Brief summary

The purpose of this study is to to assess the ability of 5 Gastro-Intestinal (GI) surgeons, within liver surgery, the readers, to identify pre-defined anatomical landmarks in liver images processed by HS2, and assessment of landmark distance between CT and Holographic visualization (HV).

Detailed description

This is a retrospective investigation of Computer Topographies (CTs)/ Holographic visualization based on CTs retrieved from patients with metastases in the liver from colorectal cancer. The study consists of: * Preparations at Day 0. The reader is not involved in the preparation * Using of HS2 and evaluation at Day 1-2 * Calculation at Day 3. The study will enroll eligible subject's images.

Interventions

DEVICEHolocare Studio 2 (HS2)

3D HV

Sponsors

HoloCare AS
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Livers with colorectal cancer liver metastasis 2. CTs from individuals 22 years or older 3. CTs retrieved from US hospitals 4. CTs from patients treated in the US 5. At least 1 visible liver lesion to complete detection of L1

Exclusion criteria

No

Design outcomes

Primary

MeasureTime frameDescription
Identification of all pre-defined landmarks.3 daysAll readers able to identify all pre-defined landmarks.

Secondary

MeasureTime frameDescription
Comparison between CT and HV distance.3 daysComparison between CT and HV distance in mm between a marker in a defined center of each portal landmark (difference less than 8.0 mm).
Comparison of image quality between CT and HV.3 daysComparison of image quality between CT and HV on a 5-graded scale (1=HV significantly poorer quality than CT, 2=HV somewhat poorer quality than CT, 3=HV as good as CT, 4=HV somewhat better than CT, 5=HV significantly better than CT). More than 50% should be scored as HV as good as CT or better. All five readers scoring 3 or higher.
Evaluate ease of use.3 daysEvaluate ease of use on a 5-graded scale (1=very difficult, 2=difficult, 3=neither difficult nor easy, 4=easy, 5=very easy). All five readers scoring 4 or 5.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026